• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)

    2/9/24 4:16:20 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $LMDX alert in real time by email
    SC 13G/A 1 p24-0326sc13ga.htm LUMIRADX LIMITED
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
     

    LumiraDx Limited

    (Name of Issuer)
     

    Common Shares, par value $0.0000028 per share

    (Title of Class of Securities)
     

    G5709L109

    (CUSIP Number)
     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. G5709L10913G/APage 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Senvest Management, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    8,072,781 Common Shares (including 5,575,474 Common Shares issuable upon conversion of the Issuer's A Ordinary Shares, par value $0.0000028 per share (the "A Ordinary Shares"))

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    8,072,781 Common Shares (including 5,575,474 Common Shares issuable upon conversion of A Ordinary Shares)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    8,072,781 Common Shares (including 5,575,474 Common Shares issuable upon conversion of A Ordinary Shares)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.1% of the Common Shares

    2.5% of the economic interest of the Common Shares and the A Ordinary Shares

    3.2% of the aggregate voting power of the Common Shares and the A Ordinary Shares

    12

    TYPE OF REPORTING PERSON

    OO, IA

             

     

     

    CUSIP No. G5709L10913G/APage 3 of 7 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Richard Mashaal

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Canada

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    8,072,781 Common Shares (including 5,575,474 Common Shares issuable upon conversion of A Ordinary Shares)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    8,072,781 Common Shares (including 5,575,474 Common Shares issuable upon conversion of A Ordinary Shares)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    8,072,781 Common Shares (including 5,575,474 Common Shares issuable upon conversion of A Ordinary Shares)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.1% of the Common Shares

    2.5% of the economic interest of the Common Shares and the A Ordinary Shares

    3.2% of the aggregate voting power of the Common Shares and the A Ordinary Shares

    12

    TYPE OF REPORTING PERSON

    IN, HC

             

     

     

     

    CUSIP No. G5709L10913G/APage 4 of 7 Pages

      

    Item 1(a). Name of Issuer:
      LumiraDx Limited (the "Issuer")

     

    Item 1(b). Address of Issuer's Principal Executive Offices:
     

    c/o Ocorian Trust (Cayman) Limited

    PO Box 1350, Windward 3, Regatta Office Park

    Grand Cayman KY1-1108

    Cayman Islands

     

    Item 2(a). Name of Person Filing:
      This statement is filed by Senvest Management, LLC and Richard Mashaal.
       
      The reported securities are held in the account of Senvest Master Fund, LP, Senvest Technology Partners Master Fund, LP and Senvest Global (KY), LP (collectively, the "Investment Vehicles").
       
      Senvest Management, LLC may be deemed to beneficially own the securities held by the Investment Vehicles by virtue of Senvest Management, LLC's position as investment manager of the Investment Vehicles. Mr. Mashaal may be deemed to beneficially own the securities held by the Investment Vehicles by virtue of Mr. Mashaal's status as the managing member of Senvest Management, LLC. None of the foregoing should be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.

     

    Item 2(b). Address of Principal Business Office:
     

    Senvest Management, LLC

    540 Madison Avenue, 32nd Floor

    New York, New York 10022

       
     

    Richard Mashaal

    c/o Senvest Management, LLC

    540 Madison Avenue, 32nd Floor

    New York, New York 10022

     

    Item 2(c). Place of Organization:
      Senvest Management, LLC – Delaware
       
      Richard Mashaal – Canada

     

    Item 2(d). Title of Class of Securities:
      Common Shares, par value $0.0000028 per share

     

    Item 2(e). CUSIP Number:
      G5709L109
       

     

     

    CUSIP No. G5709L10913G/APage 5 of 7 Pages

     

     

    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:
      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) ¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

      (g) ¨

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).
     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:                                                                                      

     

    Item 4. Ownership:
     

    The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page, including the footnote included thereto, for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The percentages of the Common Shares set forth in this Schedule 13G/A are calculated based upon an aggregate of 154,224,500 Common Shares outstanding as of December 31, 2022, as reported in the Issuer's Annual Report on Form 20-F for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission on May 1, 2023 (the "Form 20-F").

     

    The percentages of the economic interest of the Common Shares and the A Ordinary Shares and of the aggregate voting power of the Common Shares and the A Ordinary Shares on row (11) of the cover page for each Reporting Person are calculated based upon an aggregate of (i) 154,224,500 Common Shares and (ii) 164,321,766 A Ordinary Shares, in each case, outstanding as of December 31, 2022, as reported in the Form 20-F.

     

     

    CUSIP No. G5709L10913G/APage 6 of 7 Pages

     

     

    Item 5. Ownership of Five Percent or Less of a Class:
      Not applicable.

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person:
      The Investment Vehicles have the right to receive and the power to direct the receipt of dividends from, and the proceeds from the sale of the Common Shares.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:
      Not applicable.

     

    Item 8. Identification and Classification of Members of the Group:
      Not applicable.

     

    Item 9. Notice of Dissolution of Group:
      Not applicable.

     

    Item 10. Certification:
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
       

     

     

     

    CUSIP No. G5709L10913G/APage 7 of 7 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date:  February 9, 2024  
      SENVEST MANAGEMENT, LLC
       
      By:  /s/ Bobby Trahanas
      Name:  Bobby Trahanas
      Title:    Chief Compliance Officer
       
       
       
       
      /s/ Richard Mashaal
      RICHARD MASHAAL

     

    Get the next $LMDX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LMDX

    DatePrice TargetRatingAnalyst
    3/11/2022$13.00 → $9.00Outperform
    Raymond James
    11/15/2021$20.00Outperform
    Evercore ISI Group
    10/27/2021$12.00Buy
    BTIG Research
    10/25/2021$13.00Outperform
    Raymond James
    More analyst ratings

    $LMDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th

    LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX)(the "Company") today announced that it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") that its securities will be suspended from trading at the open of business on January 9, 2024 as a result of the Company's failure to maintain compliance with Nasdaq's continued listing standards. As previously disclosed, on October 24, 2023, the Company received a notice from Nasdaq's Listing Qualifications Department (the "Staff") stating that the Company's securities were subject to delisting from The Nasdaq Global Market due to a failure to maintain compliance with the minimum bid price requirement of Nasd

    1/5/24 5:45:23 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche

    LONDON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX) (the "Company"), a next generation point of care diagnostics company, announced today the appointment of joint administrators for two of its subsidiaries. The administrators have signed a definitive agreement to sell certain companies of the LumiraDx group related to LumiraDx's innovative point of care technology to Roche. The Company announced today that Andrew Johnson, Lisa Rickelton and Lindsay Hallam of FTI Consulting LLP have been appointed as joint administrators of two of its subsidiaries, LumiraDx Group Limited and LumiraDx International Limited, which together hold substantially all of the assets of the Lumi

    12/29/23 4:15:50 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal

    LONDON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- On October 24, 2023, LumiraDx Limited (NASDAQ:LMDX)(the "Company") received a notice ("Notice") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") stating that on April 21, 2023, the Staff had notified the Company that the bid price of its listed securities had closed at less than $US1.00 per share over the previous 30 consecutive business days, and, as a result, did not comply with Listing Rule 5450(a)(1) (the "Minimum Bid Requirement"). Therefore, in accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until October 18, 2023, to regain compliance with the Minimu

    10/27/23 4:45:02 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LMDX
    SEC Filings

    View All

    SEC Form 6-K filed by LumiraDx Limited

    6-K - LumiraDx Ltd (0001685428) (Filer)

    2/6/24 4:34:15 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 6-K filed by LumiraDx Limited

    6-K - LumiraDx Ltd (0001685428) (Filer)

    12/29/23 4:26:15 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 6-K filed by LumiraDx Limited

    6-K - LumiraDx Ltd (0001685428) (Filer)

    12/8/23 7:15:38 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LMDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James reiterated coverage on LumiraDx with a new price target

    Raymond James reiterated coverage of LumiraDx with a rating of Outperform and set a new price target of $9.00 from $13.00 previously

    3/11/22 7:22:18 AM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Evercore ISI Group initiated coverage on LumiraDx with a new price target

    Evercore ISI Group initiated coverage of LumiraDx with a rating of Outperform and set a new price target of $20.00

    11/15/21 8:56:20 AM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    BTIG Research initiated coverage on LumiraDx with a new price target

    BTIG Research initiated coverage of LumiraDx with a rating of Buy and set a new price target of $12.00

    10/27/21 8:35:45 AM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LMDX
    Leadership Updates

    Live Leadership Updates

    View All

    LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th

    LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX)(the "Company") today announced that it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") that its securities will be suspended from trading at the open of business on January 9, 2024 as a result of the Company's failure to maintain compliance with Nasdaq's continued listing standards. As previously disclosed, on October 24, 2023, the Company received a notice from Nasdaq's Listing Qualifications Department (the "Staff") stating that the Company's securities were subject to delisting from The Nasdaq Global Market due to a failure to maintain compliance with the minimum bid price requirement of Nasd

    1/5/24 5:45:23 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche

    LONDON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX) (the "Company"), a next generation point of care diagnostics company, announced today the appointment of joint administrators for two of its subsidiaries. The administrators have signed a definitive agreement to sell certain companies of the LumiraDx group related to LumiraDx's innovative point of care technology to Roche. The Company announced today that Andrew Johnson, Lisa Rickelton and Lindsay Hallam of FTI Consulting LLP have been appointed as joint administrators of two of its subsidiaries, LumiraDx Group Limited and LumiraDx International Limited, which together hold substantially all of the assets of the Lumi

    12/29/23 4:15:50 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LMDX
    Financials

    Live finance-specific insights

    View All

    LumiraDx Reports Second Quarter 2023 Results

    LONDON, Aug. 24, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its second quarter ended June 30, 2023. Second quarter 2023 revenues of $21.0 millionSubmitted First 510(k) Application to the U.S. Food and Drug Administration (FDA) for 5-minute COVID Ultra testSubmitted COVID/Flu combo test for FDA Emergency Use Authorization (EUA) as part of the NIH's Independent Test Assessment (ITAP) programMore than 1,500 new instruments shipped in Q2, primarily to U.S. pharmacy locations to expand testing capacity for the upcoming respiratory season Ron Zwanziger, Chairman and CEO of LumiraD

    8/24/23 7:45:00 AM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24

    LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited  (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 24, 2023. On the day of the release, LumiraDx will host a conference call and webcast at 8:30 AM Eastern Time to review the financial results and business highlights.    LumiraDx Second Quarter 2023 Financial Results Conference Call  Date:Thursday, August 24, 2023Time:8:30 AM Eastern Time   Live Call/Webcast:   Register to join by phone here.  View webcast: https://investors.lumiradx.com/news-and-events/investor-calendar    A replay of the webcast will be available on the Inv

    8/16/23 4:30:00 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    LumiraDx Reports First Quarter 2023 Results

    LONDON, May 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its first quarter ended March 31, 2023. First quarter 2023 revenues of $22.2 million.Cost reduction programs implemented across the global organization resulting in declining operating losses.US Clinical Studies for first 510K submission completed.More than 100 customers in the first full launch quarter for the world's first quantitative finger stick NT-proBNP assay. Ron Zwanziger, Chairman and CEO of LumiraDx, stated, "Our transition to non-COVID is beginning to develop, especially with the commercial launches of HbA1c

    5/16/23 7:45:00 AM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LMDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)

    SC 13G/A - LumiraDx Ltd (0001685428) (Subject)

    2/12/24 4:06:57 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)

    SC 13G/A - LumiraDx Ltd (0001685428) (Subject)

    2/9/24 4:16:20 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13D/A filed by LumiraDx Limited (Amendment)

    SC 13D/A - LumiraDx Ltd (0001685428) (Subject)

    12/29/23 1:52:49 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care